Arbutus gets FDA clinical hold lifted on AB-101, expands Pfizer/BioNTech patent suits
Arbutus reported a $337.5 million cash position for the third quarter of 2026 and said the FDA cleared AB-101 for further U.S. development while it widened LNP patent litigation against Pfizer and BioNTech.
SEC filing